Discovery Life Sciences partners with Olink to support proteomics research and accelerate precision medicine programs

UPPSALA, Sweden,, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced that it has entered into an agreement with Discovery Life Sciences™ (Discovery) to establish the largest commercial platform of the Olink^® technology in the Americas outside of Olink, and provide the market with a global "one-stop shop" to support the discovery and validation of proteomics at scale and with high specificity across all major biological pathways and sample matrices.

“Protein biomarker discovery can help bridge the gap between genomes and phenotypes, enabling improved understanding of real-time human biology and a stronger grasp of the transition from health to disease. With its high specificity, precision, and sensitivity, at scale, Olink’s PEA technology addresses limitations that historically impeded advanced proteomics,” said Jon Heimer, CEO of Olink. “We are excited to support Discovery Life Sciences on their mission to embrace the promise of proteomics through our innovative and unique technology and help leverage its potential for their customers worldwide.”

Olink’s agreement with Discovery, which includes Olink^® Explore and the Signature Q100 instrument, represents the latest addition to the rapidly growing community of service providers. This group is collectively embracing Olink’s proteomics platform, from high-plex to low-plex and across major geographies around the world, further growing the proteomics market and increasing Olink’s reach with new customers.

“Olink’s PEA technology is a unique antibody-based proteomic technology with features that solve the dynamic range issue that has hindered proteomics: allowing the detection and quantitation of low and high abundant proteins,” said Michael Pisano, Ph.D., Executive Vice President of Proteomics at Discovery. “Discovery is excited to add this significant installation of the Olink^® technology to our extensive menu of proteomic services and optimized workflows that accelerate precision medicine programs through every stage of development, at any scale.”

Discovery will offer Olink^® PEA technology to complement their genomic, cell biology, and tissue biomarker services, providing multi-omic analyses that inform and accelerate decision-making throughout drug and diagnostic development.

Investor contact
Jan Medina, CFA
VP Investor Relations & Capital Markets
Mobile: +1 617 802 4157
jan.medina@olink.com

Media contact
Andrea Prander
Corporate Communications Manager
Mobile: +46 768 775 275
andrea.prander@olink.com

About
Olink Holding AB (publ) (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major pharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The Company was founded in 2016 and is well established across Europe, North America and Asia. Olink is headquartered in Uppsala, Sweden.

About Discovery Life Sciences
Discovery Life Sciences is the company of Biospecimen and Biomarker Specialists, combining the world’s largest commercial biospecimen inventory and procurement network with preeminent multi-omic biomarker service laboratories, including genomic, tissue biomarker, proteomic, and cell-based services to accelerate new therapies supported by biomarker and companion diagnostic programs for cancer, infectious disease, and other rare and complex conditions. Through AllCells, our cell and gene therapy division, we offer one of the largest recallable donor pools, Research Use Only (RUO) and clinical-grade (GMP) fresh and cryopreserved human cellular materials to support cell and gene therapy programs at any scale from start to finish. Driven by leading scientific expertise and innovative use of current technologies, the Discovery team engages and consults with customers to rapidly overcome obstacles and obtain results to make critical research and development decisions at market-leading speed. We are Science at your Service™! For more information, visit dls.com.

Forward-Looking Statements
This release may contain forward-looking statements within the meaning of applicable securities laws, including the U.S. Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Olink’s strategy, business plans and focus. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs as of the date hereof and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those related to Olink’s business, operations, supply chain, strategy, goals and anticipated timelines, including for the delivery of Olink Explore 3072 and the expansion of the Explore platform, competition, and other risks identified in the section entitled “Risk Factors” in Olink’s Registration Statement on Form F-1, as amended (File No. 333-253818) filed with the U.S. Securities and Exchange Commission (SEC) and in the other filings, reports, and documents Olink files with the SEC from time to time. Olink expressly disclaims any obligation to update any forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.